natgillin/translations-raw huggingface dataset:
The composition of claim 7 further comprising at least one additional compound having therapeutic benefits for HCV wherein the compound is selected from the group consisting of interferons, cyclosporins, interleukins, HCV metalloprotease inhibitors, HCV serine protease inhibitors, HCV polymerase inhibitors, HCV helicase inhibitors, HCV NS4B protein inhibitors, HCV entry inhibitors, HCV assembly inhibitors, HCV egress inhibitors, HCV NS5A protein inhibitors, HCV NS5B protein inhibitors, and HCV replicon inhibitors. 
Smjesa prema zahtjevu 7, naznačena time što dalje sadrži barem jedan dodatni spoj s terapijskim učinkom na virus hepatitisa C (HCV) pri čemu se taj spoj izabire iz skupine koja obuhvaća interferone, ciklosporine, interleukine, inhibitore metaloproteaze HCV-a, inhibitore serin proteaze HCV-a, inhibitore polimeraze HCV-a, inhibitore helikaze HCV-a, inhibitore proteina NS4B HCV-a, inhibitore ulaska HCV-a, inhibitore nakupljanja HCV-a, inhibitore izlaska HCV-a, inhibitore proteina NS5A HCV-a, inhibitore proteina NS5B HCV-a i inhibitore replikacije HCV-a.
B represents a covalent bond or an alkylene group having from 1 to 5 carbon atoms, and said alkylene group being unsubstituted or substituted by an oxo group when R3 represents a heterocyclic group; 
B predstavlja kovalentnu vezu ili alkilensku skupinu s 1 do 5 atoma ugljika, gdje je navedena alkilenska skupina nesupstituirana ili je supstituirana s okso skupinom kada R3 predstavlja heterocikličku skupinu;
This results in low yields, as the needed sizes do not necessarily match the size of the plywood panel. 
Posljedica toga je mali korisni učinak, budući da veličine koje su potrebne nisu nužno usklađena s veličinom ploče od šperploče.
The compound of Claim 1, wherein the crystalline form is Compound 1 free base anhydrate, characterized by a powder X-ray diffraction pattern having at least one peak selected from those at 6.3, 7.1, 9.0, 9.5, 12.5, 14.5, 14.7, 15.9, 16.9, and 18.9 degrees 2θ (pattern A), each peak being ± 0.2 degrees 2θ, when measured at about 25°C with Cu Ka radiation at 1.54178 A. 
Spoj u skladu s patentnim zahtjevom 1, pri čemu je kristalni oblik slobodna baza anhidrata Spoja 1, naznačen time, da ga karakterizira rendgenski difraktogram praha koji ima najmanje jedan pik odabran od sljedećih vrijednosti: 6.3, 7.1, 9.0, 9.5, 12.5, 14.5, 14.7, 15.9, 16.9 i 18.9 stupnjeva 2θ (uzorak A), pri čemu je svaki vrh ± 0.2 stupnjeva 2θ, izmjereno pri približno 25 °C uz Cu Ka zračenje na 1,54178 Å.
The apparatus of claim 1, wherein the aluminum alloy is selected from the group consisting of AA5754, AA5052 and AA6061. 
Uređaj prema zahtjevu 1, naznačen time da je aluminijska legura odabrana iz skupine koja se sastoji od AA5754, AA5052 i AA6061.
polynucleotide encoding a polypeptide consisting of the sequence set forth in the group consisting of (a) SEQ ID NO: 6; 
polinukleotid koji kodira polipeptid koji se sastoji od slijeda iznijetog u skupini koju čine SEQ ID NO: 4, 6, 12 i 14;
a polynucleotide comprising the nucleotide sequence encoding a heterologous product of interest, the expression of which is controlled by a first SFV subgenomic promoter (SG1); and 
(a) Polinukleotid koji sadrži nukleotidnu sekvencu koja kodira hetereologni proizvod od interesa, ekspresiju kojeg kontrolira prci SFV subgenomski promotor (SG1); i
The nucleotide 2′-deoxythymidine-5′-monophosphate (dTMP), on the other hand, is produced by de novo synthesis from 2′-deoxyuridine-5′-monophosphate (dUMP), a conversion catalysed by the enzyme thymidylate synthase. 
Nukelotid 2'-deoksitimidin-5'-monofosfat (TMP), u drugu ruku, proizvodi se sintezom de novo iz 2'-deoksiuridin-5'- monofosfat (UMP), konverzijom koju katalizira enzim timidilat sintaza.
said groove (22) being a T-groove with inverted T-shape 
navedeni žljeb (22) je T-žljeb preokrenutog T-oblika
The reaction mixture was heated at 85° C. After the reaction was complete, it was diluted with ethyl acetate, washed with 1N NaOH, brine and dried over anhydrous Na2SO4. 
Reakcijska smjesa se zagrijava na 85% C. Nakon završetka reakcije, razrijedi se etil acetatom, ispere IN NaOH, otopinom soli i suši iznad anhidridnog Na,SOy.
The method of claim 1, wherein the compound is or a pharmaceutically acceptable salt or a solvate thereof. The method of claim 1 wherein the depressive disorder is selected from the group consisting of major depressive disorder, persistent depressive disorder (dysthymia) and substance-medication-induced depressive disorder. 
Spoj ili farmaceutski pripravak za uporabu prema zahtjevu 11 ili 12, naznačen time što su stanja ili bolesti središnjeg živčanog sustava odabrane iz skupine koju čine demencija ili neurokognitivni poremećaj, veliki depresivni poremećaj, depresija, depresija rezistentna na liječenje, poremećaj pažnje s hiperaktivnošću i shizofrenija.
A compound that binds to and activates the erythropoietin receptor (EPO-R), which compound comprises a peptide dimer having the formula: where 
Spoj koji se veže na i aktivira eritropoctinski receptor (EPO-R), gdje navedeni spoj sadrži peptidni dimer formule:
The present invention thus provides 2-(R)-phenylpropionic acid derivative compounds of formula (I): 
L Spojevi derivata 2(R)"enilpropionske kiseline, naznačeni time, da su opće formule (1)
Magnetic Optically Variable Pigment* 
Magnetski optički varijabilni pigment*
The vector of claim 13 for use in a method of medical treatment. 
Vektor prema zahtjevu 13, naznačen time, da se upotrebljava u postupku medicinskog liječenja.
The process of claim 2, 3 or 4, wherein the coupling step (e') comprises the steps: coupling the compound of formula (XVIII) with a compound of formula (XIXa), in the presence of N-methylmorpholine in DMF; 
spajanja spoja formule (XVIII) sa spojem formule (XIX) gde X je OH u prisutnosti2-(1H-benzotriazol-1-il)-1,1,3,3-tetrametiluronij tetrafluoroborata (TBTU) i tercijarnog amina u diklorometanu;
A compound according to claim 11 for the treatment of Parkinson's disease or Huntington's disease in a mammal, such as a human subject. 
Tvar u skladu s patentnim zahtjevom 4 za uporabu u liječenju Parkinsonove bolesti ili Huntingtonove bolesti u sisavaca.
obtaining the nucleotide sequence of a parent protein encoding sequence of a parent virus 
dobivanje nukleotidne sekvence proteina koji kodira regiju matičnog virusa;
said carbonate base is selected from the group consisting of LiHCO3, NaHCO3, KHCO3, Li2CO3, Na2CO3, and K2CO3. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedenu karbonatnu bazu se bira iz skupine koju čine LiHCO3, NaHCO3, KHCO3, Li2CO3, Na2CO3 i K2CO3.
wherein R2 and R6 are as defined for the compound of formula (II), and 
)-NH, R6 gdje su R2 i R6 kao što su definirani za spoj formule (IJ), i
optionally wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof. 
Stanica domaćina prema patentnom zahtjevu 24, gdje je spomenuta stanica domaćina najmanje izabrana iz COS-1, COS-7, HEK293, BHK21, CHO, BSC-I, Hep G2, 653, SP2/0, 293, HeLa, mijeloma, ili stanica limfoma, ili bilo kojeg derivata, imortalizovanih-besmrtnih ili transformisanih ćelija od njih.
A pharmaceutical kit suitable for the in situ formation, in a subject, of a biodegradable implant comprising the injectable depot composition according to claim 1, wherein, prior to mixing with the DMSO the drug and the biocompatible copolymer are contained in a first container, and the DMSO is contained in a second, separate container. 
Farmaceutski komplet za in situ formiranje biorazgradivog implantata u tijelu koji sadrži sastav iz bilo kojeg od patentnih zahtjeva 1 do 12, naznačen time što su lijek i biorazgradivi polimer sadržani u prvom spremniku, a otapalo se nalazi u drugom, zasebnom spremniku.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
The pharmaceutical composition of claim 5, wherein in Formula (I'), R1 is a hydrogen atom, and R2 is a hydrogen atom; a hydroxy group; a straight or branched C1-C6 alkyl group; a straight or branched C1-C5 alkoxy group; or a straight or branched C1-C3 thioalkyl group. 
Spoj formule (T') iz patentnog zahtjeva 5 za njegovu primjenu prema patentnom zahtjevu 5, gdje u formuli (T), R' je atom vodika, i R* je atom vodika; hidroksi grupa; ravna ili razgranata C,-C4 alkil grupa; ravna ili razgranata C;- Cs alkoksi grupa; ili ravna ili razgranata C;-Cz tioalkil grupa.
Accordingly, the invention also includes a method of treatment in the field of male hormone replacement therapy comprising the administration, to a male of a compound as described hereinbefore (in a suitable pharmaceutical dosage form). 
Prema tome, ovaj izum također uključuje postupak liječenja u području hormonske zamjenske terapije kod muškaraca, koji se sastoji u primjeni na muškarcu spoja opisanog gore u ovoj specifikaciji (u pogodnom farmaceutskom obliku doziranja).
wherein R9 represents an optionally substituted aromatic 5 membered monocyclic heterocyclyl, for example unsubstituted imidazolyl (e.g. 
gdje R9 predstavlja supstitut po izboru za aromatizirani 5-člani monociklički heterociklil, na primjer nesupstituirani imidazolil (npr.
The process according to claim 6, characterised in that the preliminary treatment step (130) is carried out on the white slag (14), on the black slag (15) and on the refractory materials (16). 
Postupak prema zahtjevu 6, naznačen time što se preliminarni korak obrade (130) provodi za bijelu trosku (14), crnu trosku (15) 1 na refraktornim materijalima (16).
The composition of claim 1 further comprising at least one substance selected from essential oils and plant extracts. 
barem jednu supstancu odabranu od egzogenih soli, antimikrobnih sredstava, aminokiselina i esencijalnih ulja;
The process of paragraph 46, wherein said second solvent is selected from the group consisting of methanol, ethanol, propanols, and butanols, xylene, N-methylpyrrolidinone, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine metanol, etanol, propanoli i butanoli, ksilen, N-metilpirolidinon, te smjese 2 ili više njih.
More preferred compositions comprise: artemether and a pharmaceutically-acceptable excipient selected from the group consisting of: medium chain length triglycerides; short chain triglycerides; and omega-3-marine triglycerides, said composition formulated for transmucosal sublingual, buccal or nasal dosage, and especially a composition consisting essentially of: artemether and a pharmaceutically-acceptable excipient selected from the group consisting of: medium chain length triglycerides; short chain triglycerides; and omega-3-marine triglycerides, said composition formulated for transmucosal sublingual, buccal or nasal dosage. 
Kompozicija prema patentnom zahtjevu 1 naznačena time što se uglavnom sastoji od: artemetra ili arteetra; i farmaceutski prihvatljivog inertnog punitelja izabranog iz grupe koju čine: trigliderid tekući na 37*C; i trigliceridi srednje dužine lanca; pri čemu je navedena kompozicija formulirana za transmukozalnu subligvalnu, bukalnu ili nazalnu dozu.
The aqueous pharmaceutical suspension according to claim 3, wherein the propylparaben, sodium propylparaben, or potassium propylparaben is, by weight/volume (g/100 mL), 0.014% to 0.048%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što propilparaben, natrij- propilparaben ili kalij-propilparaben iznosi, težinskifvolumno (g/100 ml), otprilike 0,014 % do otprilike 0,048 %.
An oligonucleotide according to claim 5, wherein said oligonucleotide comprises at least one nucleotide analogue with one sugar moiety that is monosubstituted at the 2', 3' and/or 5' position, preferably at the 2'-position, and more preferably the sugar moiety is 2'-methoxy substituted. 
9. - Oligonukleotid u skladu s patentnim zahtjevom 5, naznačen time što navedeni oligonukleotid sadrži najmanje jedan nukleotidni analog s jedim šećernim ostatkom monosupstituiranim na položaju 2", 3 1/ili 5", po mogućnosti na 2'-položaju, a poželjnije gdje je šećerni ostatak 2'-metoksi supstituiran.
A pharmaceutical composition according to clause 24, wherein the coating layer comprises coating agents, plasticizers, antitacking agents, surfactants, coloring agents, opacifiers or mixtures thereof. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 23, naznačen time da sloj obloge sadrži sredstva za oblaganje, plastifikatore, sredstva protiv sljepljivanja, površinski aktivne tvari, bojila, sredstva za postizanje neprozirnosti ili mješavine istih.
The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is in the form of an aqueous suspension or dispersion. 
Farmaceutski sastav prema zahtjevu 5, naznačen time, da je farmaceutski sastav u obliku vodene suspenzije ili disperzije.
kg woman diagnosed with postmenopausal osteoporosis is prescribed the enteric-coated oral dosage form of Example 1, to be taken once weekly, comprising 35 mg risedronate and 100 mg Disodium EDTA. 
Oralni oblik za doziranje prema zahtjevu 1, naznačen time da je isti tableta koja sadrži a) 35 mg natrijevog risedronata koji je baziran na anhidridu risedronatne mononatriejve soli; i b) 100 mg dinatrijeve EDTA.
The subject matter of claim 11, wherein the recombinant adenovirus selectively expresses E1a-12S or E1a13S. 
Predmetni sadržaj prema zahtjevu 11, gdje rekombinantni adenovirus selektivno eksprimira E1a-125 ili Ela13S.
A method of making a fusion protein encoded by the nucleic acid sequence of claim 13, comprising expressing the fusion protein encoded by the vector of claim 15 in the host cell of claim 18, and isolating the expressed protein. 
Postupak izrade fuzijskog proteina sukladno bilo kojem od patentnih zahtjeva 1-5, koji sadrži ekspresiju fuzijskog proteina kodiranog nukleinskom kiselinom u vektoru sukladnopatentnom zahtjevu 12 i izoliranje eksprimiranog proteina.
Combination according to claim 19, in which said amphotericin is amphotericin B. 
Kombinacija prema zahtjevu 27, kod koje je amfotericin amfotericin B, a naročito kao deoksikolat ili u liposomnom obliku.
The reaction was filtered and concentrated. 
Reakcija je filtrirana i koncentrirana.
In vivo protection against ischemia-reperfusion damage in the heart. 
In vivo zaštita od ozljede srca zbog ishemije-reperfuzije.
The method of clause 48 or 49, wherein said matrix is selected from the group consisting of: laminin, fibronectin, vitronectin, proteoglycan, entactin, collagen, collagen I, collagen IV, heparan sulfate, Matrigel (a soluble preparation from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells), a human basement membrane extract, and any combination thereof. 
Postupak u skladu s patentnim zahtjevom 5 ili 6, naznačen time što se matriks bira iz skupine koju čine: laminin, fibronektin, vitronektin, proteoglikan, entaktin, kolagen, kolagen I, kolagen IV, heparan-sulfat, topljivi pripravak iz stanica mišjeg Engelbreth-Holm-Swarm (EHS) sarkoma, ekstrakt ljudske bazalne membrane, te bilo koja njihova kombinacija.
A pharmaceutical composition for use according to claim 11 wherein the pharmaceutical composition further comprises D-serine, D-serine ethyl ester, D-cycloserine, amantadine, amantadine hydrochloride, buspirone, acetazolamide, topiramate, divalproex sodium, L-dopa, propranolol, primidone, clonazepam, levetiracetam, carbamazepine, gabapentin, baclofen, ondansetron, tizanidine or pramipexole. 
Farmaceutski pripravak za uporabu prema zahtjevu 11 naznačen time da farmaceutski pripravak nadalje sadrži D-serin, D-serin etil ester, D-cikloserin, amantadin, amantadin hidroklorid, buspiron, acetazolamid, topiramat, divalproeks natrij, L-dopa, propranolol, primidon, klonazepam, levetiracetam, karbamazepin, gabapentin, baklofen, ondansetron, tizanidin ili pramipeksol.
A compound of formula IIa: 
Spoj formule IIa:
and R2, for each occurrence are, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; or R1 and R2 taken together with the nitrogen to which they are attached is optionally substituted heterocyclyl or optionally substituted heteroaryl; 
R; i Ro, za svaku pojavu su, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; ili R; i R» uzeti zajedno s dušikom na kojeg su vezani su opcijski supstituiran heterociklil ili opcijski supstituiran heteroaril;
Use according to claim 8, wherein the delivery system releases the alpha-MSH analogue for a period of at least 2 days. 
Uporaba u skladu s patentnim zahjevom 5, pri čemu sustav za isporuku otpušta alfa-MSH analogu u periodu od najmanje 2 dana.
The method in of claim 6 or 7, wherein a saponification step is carried out before the extraction of the cholesterol. 
Postupak u skladu s patentnim zahtjevom 9 ili 10, naznačen time što se prije ekstrakcije kolesterola provodi korak saponificiranja.
In one embodiment, the blended wax comprises a blend of four paraffinic or similarly petrochemically derived wax cuts. In this embodiment, the first wax cut preferably comprises a melting point in the range 48-50° C., the second wax preferably cut comprises a melting point in the range 54-57° C., the third wax cut preferably comprises a melting point in the range 60-62° C. and the fourth wax cut preferably comprises a melting point in the range 65-68° C. 
Miješani vosak u skladu s patentnim zahtjevom 2, naznačen time što miješani vosak sadrži četiri reza voska, te što prvi rez voska ima talište u rasponu od 48-50 *C, gdje drugi rez voska ima talište u rasponu od 54-57 "C, gdje treći Tez voska ima talište u rasponu od 60-62 "C, te gdje četvrti rez voska ima talište u rasponu od 65-68 *C.
And wherein a processor (14) is further provided, configured to compare the coordinates received from the satellite with the ones contained in the memory so as to configure the monitor to the reception of the images of a specific sentinel apparatus in correspondence of the reaching of the train of the activation distance from the said sentinel apparatus and de-activating the monitor once the train has reached the de-activation point and the processor has recognized such a condition. 
- te pri čemu je dodatno predviđen procesor (14), konfiguriran za uspoređivanje koordinata primljenih od satelita s koordinatama sadržanim u memoriji tako da se konfigurira monitor za prijem slika za specifični nadzorni uređaj u skladu s nadolaskom vlaka na aktivacijsku udaljenost od navedenog nadzornog uređaja 1 deaktivaciju monitora nakon što je vlak stigao do de-aktivacijske točke i procesor je takvo stanje prepoznao.
An inserter for an intrauterine system, comprising 
Aplikator za umetanje za intrauterini sustav, obuhvaća
(wherein R1R2 and R3 have the meanings defined in formula (1) and R6 is 2-hydroxy phenyl) with carbonyl dimidazole or thiocarbonyl diimidazole in a suitable solvent such as dichloromethane and subsequent reaction of the products this formed with the amine HNR4R5. 
(gdje Ri, R, i Rz znače kao što je definirano za formulu (1), a R4 je 2-hidroksifenil) s karbonildiimidazolom ili tiokarbonildiimidazolom, u pogodnom otapalu, poput diklormetana, te naknadnom reakcijom tako dobivenih produkata s aminom HNRRs.
substituted at 3-position or 4-position on the benzene ring of the matrix; wherein one end of atom N is connected with the matrix; 
Lje supstituiran na poziciji 3 ili 4 na benzenskom prstenu matrice; pri čemu je jedan kraj atoma N povezan sa matricom;
The antibody of any of paragraphs 84, 85, 98, 90, or 91 wherein the antibody binds an epitope presented by a trimeric spike of gp120 on a cell surface, wherein the epitope is not presented when gp120 is artificially trimerized. 
Protutijelo u skladu s bilo kojim od patentnih zahtjeva 3 do 6, naznačeno time što se protutijelo veže na epitop kojeg prezentira trimerni šiljak gp120 na površini stanice, gdje se epitop ne prezentira kada je gp120 trimeriziran na umjetan način.
A compound of the formula: wherein Ring A, Ring B and Y are as defined in 1, and R11b, R11c and R11d are as defined in 22. 
c (ta) gdje su Prsten A, Prsten B i Y definirani kao u patentnom zahtjevu 1, naznačen time što se sastoji u reduciranju spoja formule III:
The process of clause 1, wherein at least a portion of the process occurs in equipment comprising a reaction zone, a separation zone, and a condensing zone. 
Postupak iz patentnog zahtjeva 1, pri čemu se barem dio postupka odvija u opremi koja obuhvaća reakcijsku zonu, zonu razdvajanja i zonu kondenzacije.
This detergent does not form microaggregates with IL-2, but the detergent does solubilised the IL-2 and gives a bioactive monomeric product. 
Deterdžent ne oblikuje mikroagregate s IL-2, ali deterdžent je otopio IL-2 i daje bioaktivni monomerni proizvod.
A vehicle as claimed in claim 47 in the form of a water-borne vehicle. 
Vozilo prema Zahtjevu 47, naznačeno time, da je izvedeno u obliku letjelice.
The pharmaceutical composition according to claim 1, wherein said ARB is selected from the group consisting of candesartan, irbesartan, losartan, and valsartan. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni ARB odabran 12 skupine koju čine kandesartan, irbesartan, losartan i valsartan.
A compound N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide and a pharmaceutically acceptable carrier or adjuvant, for use in modulating the activity of CFTR. 
Spoj N-(5-hidroksi-2,4-diterc-butil-fenil)-4-okso-1H-kinolin-3-karboksamid ili njegova farmaceutski prihvatljiva sol; ili farmaceutski pripravak koja sadrži N-(5-hidroksi-2,4-diterc-butil-fenil)-4-okso-1H-kinolin-3-karboksamid ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač ili adjuvant;
The composition of claim 1, the compound comprising a structure of Formula 4 or stereoisomer thereof or pharmaceutically acceptable salt thereof. 
Aa Å IERNNIA 1, tvar sadrži strukturu Formule 4 ili njen stereoizomer ili njenu farmaceutski soi Å ta Pa" pu gos
alkyl optionally substituted by hydroxy, or alkenyl, when X5 is C(R11), R10 and R11 are optionally bonded to form a 5- or 6-membered ring optionally substituted by alkyl or oxo, and when X6 is N(R12) and X7 is CH(R13), R12 and R13 are optionally bonded to form a 5- or 6-membered ring, or 
alkenil, kada X? je C(R''), R"i R su prema potrebi povezani za tvorbu 5-članog ili 6-članog prstena koji je prema potrebi supstituiran s alkilom ili okso, i kada x" je NR'?) i X' je CH(R'), R'* i R'? su prema potrebi povezani za tvorbu 5-članog 1li 6-članog prstena; ili (3) -izokromenil, ili njegova sol.
The compounds in free or salt form can be obtained in the form of hydrates or solvates containing a solvent used for crystallisation. 
Spojevi u slobodnom obliku ili u obliku soli mogu se dobiti u obliku hidrata ili solvata koji sadrže otapalo upotrijebljeno za kristalizaciju.
A method for generation of a polyclonal cell line capable of expressing a polyclonal protein comprising 2 to n distinct members, said method comprising: 
Postupak dobivanja poliklonske stanične linije koja može eksprimirati poliklonski protein, koju čine 2 do n različitih članova, naznačen time što navedeni postupak se sastoji u: